Radiologic controls were age-matched infants without known pulmonary disease ... show diffuse pulmonary involvement is stressed. The continued genesis of potentially functional parenchymal ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.

Radiographs of the cervical, thoracic, and lumbar spine reportedly showed diffuse osteopenia ... of findings includes metastatic lung cancer, metastatic disease related to a primary cancer other ...

Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

Various forms of diffuse parenchymal lung disease have been proposed as potential consequences of severe COVID‑19. We describe the clinical, radiological and histological findings of patients with ...

diffuse lung disease, 2) focal lung lesions 3) and systemic inflammatory responses and hypersensitivity (Table 1). Helminths that cause lung disease typically have either a larval migratory phase ...

Comparison of acute exacerbations of chronic obstructive pulmonary disease versus stable chronic obstructive pulmonary disease (↑: upregulated in acute exacerbations of chronic obstructive ...

Mar. 25, 2025 — Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor ...

A rare case has been reported of diffuse large B-cell lymphoma (DLBCL) presenting initially as cold agglutinin disease (CAD). The report, published in the Kaohsiung Journal of Medical Sciences, ...

"2024 was an important year for aTyr, as we completed enrollment in our global pivotal Phase 3 EFZO-FIT™ study, which is the largest interventional study ever to be conducted in pulmonary sarcoidosis, ...